Amgen Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (78)

Latest Posts

About This Stock More About This Stock
3 Breakout Stocks For March 2017
Article By: Taki Tsaklanos
Saturday, February 25, 2017 5:37 PM EST
InvestingHaven’s research team selected 3 beautiful breakout stocks. Those stocks test a long term resistance level after multiple unsuccessful attempts in the past.
In this article: DAL, AMGN, RNG
Read
Medical Devices And Healthcare Since He (Trump) Said "Pharma"
Article By: Gary Tanashian
Monday, February 20, 2017 1:42 PM EST
I’ve taken profits on the overbought IHI along with components BSX and WAT, while still holding MDT for a possible gap fill and date with the SMA 200.
In this article: BSX, CRY, MDT, WAT, IBB, AMGN, IHI, XLV
Read
Large Cap Biopharmaceuticals: Update On Financial Metrics
Article By: Rod Raynovich
Sunday, February 12, 2017 4:12 AM EST
We have updated the comparison of eight large cap biopharma stocks post 2016 earnings for the period ending 2/10/17. Keep in mind that in January 2016 there was a severe correction with stocks dropping 25-30% with lows being hit in February 2016.
In this article: BMY, ALXN, AMGN, CELG, GILD, ABBV, IBB, REGN Also: XBI
Read
Rayno Biobeat 2017 #1: Biotech Rally Driven By M&A
Article By: Rod Raynovich
Friday, February 10, 2017 4:00 PM EST
Biogen looking good in here at $275+, up 4.2% over five days, down 2.7% YTD. IBB and XBI​ slight gains.
In this article: ACOR, ALNY, ARRY, IBB, REGN, SGEN, AMGN, BIIB, CLVS, HOLX, XBI, AGIO, BLUE, FMI, TSRO
Read
Biotech Stock Roundup: Celgene, Biogen, ABBV Posted Q4 Results, Catabasis Falls On DMD Data
Article By: Arpita Dutt
Thursday, February 2, 2017 8:56 AM EST
Companies like Celgene, Biogen and AbbVie reported fourth quarter results last week. Catabasis suffered a major setback with its lead pipeline candidate edasalonexent failing to meet the primary endpoint.
In this article: REGN, XOMA, AMGN, BIIB, CELG, CATB, ABBV
Read

PARTNER HEADLINES

Latest Tweets for $AMGN

No tweets yet!